NHS – Page 3 – media

Roche’s Erivedge no longer funded by the NHS

Roche’s Erivedge will indeed no longer be funded on the National Health Service(NHS) as a treatment for skin cancer after cost regulators issued final guidance ruling that it is not cost effective.
- Source: news.open-medical
- 547
- November 27, 2017
BCC Company Insight Erivedge NHS Roche skin cancer
NHS England consults on simplifying research processes

NHS England says it is planning to accelerate the NHS’ national research strategy, “cutting bureaucracy and speeding up access to new and innovative treatments”.
- Source: Pharmatimes
- 453
- November 22, 2017
NHS polices
NHS to fund gene therapy for ‘bubble babies’

The NHS will fund gene therapy for the first time, with a £500,000 treatment for “bubble baby syndrome”.
- Source: Telegraph
- 1,047
- October 26, 2017
gene immune defiency Market Views NHS therapy
NICE flip-flops to back Bristol’s Opdivo in head and neck cancer despite data ‘uncertainties’

Back in April, England’s cost watchdogs said they wouldn’t cover Bristol-Myers Squibb’s Opdivo in head and neck cancer due to “uncertain” clinical evidence. Now, though, they’re singing a different tune.
- Source: Fiercepharm
- 550
- October 16, 2017
New Approvals NHS Opdivo
Europe’s first stem cell therapy backed by NICE

Chiesi's Holoclar, the first stem-cell therapy to be cleared by European regulators, has received a green light for use on the NHS in England and Wales to treat a rare sight condition.
- Source: pharmatimes
- 857
- August 29, 2017
New Approvals NHS stem-cell therapy
NICE turns down kidney cancer drugs

It is looking unlikely that patients in England and Wales with advanced renal cell carcinoma will be getting routine NHS access to Eisai’s Kisplyx or Eusa Pharma’s Fotivda, after cost regulators issued draft guidelines turning down their use.
- Source: pharmatimes
- 516
- August 15, 2017
cancer kidney Market Views NHS renal
NICE backs new treatment option for psoriasis

The National Institute for Health and Care Excellence has issued draft guidelines backing NHS use of Almirall’s Skilarence to treat moderate to severe plaque psoriasis.
- Source: pharmatimes
- 521
- August 9, 2017
Company Insight New Approvals NHS NICE psoriasis
Fast-track pancreatic cancer surgery boosts success, saves money

Accelerating access to pancreatic surgery has been shown to boost success rates by more than a fifth with a cost saving to the NHS of around £3,200 per patient.
- Source: pharmatimes
- 409
- August 3, 2017
Clinical Trials NHS pancreatic
NICE nods for Amgen’s rare leukaemia drug

Patients with a rare form of leukaemia look set to win routine access to a novel treatment option on the NHS in England and Wales after Amgen’s Blincyto was backed by cost watchdog NICE
- Source: pharmatimes
- 641
- May 3, 2017
cancer Company Insight NHS NICE therapy

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.